← Eichor
Study identifier: NCT07375121 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Comparison of the Efficacy and Safety of Fixed-rate Basal Infusion Mode and Time-programmed Decremental Background Infusion Mode of Intravenous PCA Following Mixed Surgery

Condition: Surgery · Pain Management · Opioid Consumption  ·  Sponsor: Beijing Tiantan Hospital

PhaseNA
Planned participants450
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

Perioperative pain management affects patient recovery. However, the rate of moderate to severe postoperative pain is as high as 73.8%, which hinders recovery and increases the risk of complications. Although opioids are the first-line analgesics, excessive use leads to adverse reactions. The traditional fixed-rate PCA mode is difficult to match the changes in postoperative pain. This study will compare different PCA mode optimization strategies, assuming that they can reduce opioid dosage, improve analgesic effect, and reduce adverse reactions, providing high-quality evidence-based basis for postoperative analgesia and promoting individualized and intelligent management.

This description comes directly from the study's public registry record.

Talk to the study team

Fang Luo  ·  59976661  ·  13611326978@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Beijing Tiantan Hospital, Beijing, Beijing 100070Beijing, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07375121